Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : PAN004,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Recipient : Wacker Chemie AG
Deal Size : Undisclosed
Deal Type : Collaboration
Wacker and Pantherna Enhance Collaboration in mRNA Biopharmaceutical Development
Details : Through the collaboration, company aims to focus on the clinical development of PAN004, which is being evaluated in the preclinical studies for the treatment of acute respiratory distress syndrome.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
July 04, 2024
Lead Product(s) : PAN004,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Recipient : Wacker Chemie AG
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Evaxion Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaxion and Pantherna Announce Promising Preclinical mRNA Vaccine Data
Details : The preclinical data demonstrate that tumor neoantigens identified by Evaxion’s AI platform, PIONEER, drive a strong immune response and lead to complete inhibition of tumor growth in a preclinical model.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 02, 2023
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Evaxion Biotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PTXmRNAs,Inapplicable
Therapeutic Area : Technology
Study Phase : Discovery
Sponsor : Astellas Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the new agreement, Pantherna’s mRNA platform and Astellas’ world-class drug discovery capabilities will be combined to promote research on the generation of regenerative medicine programs for new target organ using a direct reprogramming approa...
Product Name : PTXmRNAs
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
April 10, 2022
Lead Product(s) : PTXmRNAs,Inapplicable
Therapeutic Area : Technology
Highest Development Status : Discovery
Sponsor : Astellas Pharma
Deal Size : Undisclosed
Deal Type : Agreement